Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Industry’s Economic Value Should Preclude Price Controls, Novartis Says

Executive Summary

The pharmaceutical industry is of "strategic value" to the U.S. economy and should not be jeopardized by instituting drug price controls, Novartis CEO Daniel Vasella, PhD, told the AARP International Forum on Prescription Drug Pricing Policy June 10 in Washington, D.C

You may also be interested in...

Tidbits From The Fourth Quarter Calls, In Brief

AstraZeneca Prilosec generic erosion: AstraZeneca's Prilosec holds 47% share of total prescriptions following generic omeprazole entry in late 2002, CFO Jon Symonds says on Jan. 30 investor call. "We must, of course, be cautious with only six weeks of data available...but it's clear that the erosion rate is significantly less than that observed with either Prozac or Zestril at a similar stage, seemingly consistent with Kudco's inability to fully supply the market." Schwarz' subsidiary Kudco is distributing generic Prilosec on a limited basis due to supply constraints (1"The Pink Sheet" Dec. 16, 2002, p. 30)....Nexium ramp-up: Nexium total prescription share is over 20%, up more than eight percentage points in 2002. Share of total scripts written by gastrointestinal specialists is more than 27%...

Novartis opens Cambridge research facility

Novartis' $250 mil. investment in a 255,000 sq. ft. research facility in Cambridge, Mass. is part of the continuing trend of increasing R&D investments in the U.S. over Europe, company says. Sen. Edward Kennedy (D-Mass.) and Rep. Michael Capuano (D-Mass.) joined Novartis in a May 6 press conference announcing the opening. Research activities are scheduled to begin in the first quarter of 2003 with 400 employees, with an expansion planned to accommodate 900 scientists...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts